AUTHOR CORRECTION

"RESPIRATORY FUNCTION AND SELF-REPORTED FUNCTIONAL HEALTH: EPIC-NORFOLK POPULATION STUDY". P.K. MYINT, R.N. LUBEN, P.G. SURTEES, N.W.J. WAINWRIGHT, A.A. WELCH, S.A. BINGHAM, N.J. WAREHAM, N.E. DAY AND K-T. KHAW. *EUR RESPIR J* 2005; 26: 494–502.

Unfortunately, in the above paper forced expiratory volume in one second (FEV1) units should have read as $cL \cdot s^{-1}$ instead of $mL \cdot s^{-1}$. The authors apologise for the error.

ERRATUM

"BUDESONIDE/FORMOTEROL MAINTENANCE AND RELIEVER THERAPY: AN EFFECTIVE ASTHMA TREATMENT OPTION?" C. VOGELMEIER, A. D'URZO, R. PAUWELS, J.M. MERINO, M. JASPAL, S. BOUTET, I. NAYA AND D. PRICE. *EUR RESPIR J* 2005; 26: 819–828.

Unfortunately, in the above paper, figure 4 was printed incorrectly and should have appeared as follows.

FIGURE 4. The proportion of patients in the last 2 weeks of the study using a) low levels of as-needed medication (a maximum of 4 as-needed inhalations·week^{-1}) or b) higher levels (>4 as-needed inhalations·week^{-1}). Data are split by the average daily maintenance inhaled corticosteroid (ICS) dose, defined by guidelines [18] as: low or moderate dose, or high dose (for fluticasone patients only). SAL/FLU: salmeterol/fluticasone; BUD/FORM: budesonide/formoterol. ■: high maintenance ICS dose; ▨: moderate maintenance ICS dose; □: low maintenance ICS dose. #: n=688; ¶: n=787; +: n=350; §: n=247.

The authors have also reported a change in the Results, Overall study drug use section. The sentence "The total mean daily ICS dose in patients with high as-needed use (>4 inhalations·day^{-1}) was: budesonide 910 µg·day^{-1} (BDP equivalent 1,420 µg·day^{-1}) *versus* fluticasone 701 µg·day^{-1} (BDP equivalent 1,402 µg·day^{-1})" should read "The total mean daily ICS dose in patients with high as-needed use (>4 inhalations·week^{-1}) was: budesonide 910 µg·day^{-1} (BDP equivalent 1,420 µg·day^{-1}) *versus* fluticasone 701 µg·day^{-1} (BDP equivalent 1,402 µg·day^{-1})". The authors apologise for this error.